title: Durable responses to rituximab in acquired factor VIII deficiency.
authors.forename: Abha G
authors.initials: AG
authors.lastname: Singh
authors.forename: Iyad S
authors.initials: IS
authors.lastname: Hamarneh
authors.forename: Mark W
authors.initials: MW
authors.lastname: Karwal
authors.forename: Steven R
authors.initials: SR
authors.lastname: Lentz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D001323:Autoantibodies / Q000378:metabolism; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005169:Factor VIII / Q000276:immunology* / Q000378:metabolism; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001323:Autoantibodies; D000069283:Rituximab; D005169:Factor VIII